Hughes EC, Syed HA, Saleh D
Follow the product instructions for proper use and dosage
The oral tirzepatide gum is one of the few non-injectable options in this category, so patients who have avoided treatment specifically because of injections finally have a legitimate alternative backed by licensed prescribers
There are no scheduled check-ins, no required follow-ups, and no clear cadence for dose adjustments
Since FDA declared the semaglutide shortage resolved on February 21, 2025, ended its enforcement-discretion windows in spring 2025, and then announced new action against mass-marketed non-FDA-approved GLP-1 drugs on February 6, 2026, GLP-1 telehealth startup compliance now depends on whether you are still facilitating compounded supply or enabling noncompliant GLP-1 prescribing workflows